Here are the top 5 inflammation pieces of 2025; stay up-to-date with all the inflammation content from The American Journal ...
The company’s valuation, which surged past $40 billion this year, fell by almost a fifth on a dimmer outlook for its closely followed lung disease medicine.
Insmed shares fall after brensocatib misses Phase 2b CRSsNP endpoints, prompting program discontinuation as analysts remain ...
As an A&E nurse, Claire Davies found out in the worst way possible that flu is not ‘just a cold’ – and sharing her experience ...
Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease non-cystic fibrosis bronchiectasis (NCFB). The US regulator cleared DPP1 ...
Insmed said on Wednesday it had discontinued the development of its experimental anti-inflammatory drug to treat a chronic sinus condition after it failed to show benefit in a mid-stage study, sending ...
A greater proportion of women vs. men with COPD or bronchiectasis had their first health care visit within 6 months of ...
Recent weather patterns in the UAE have brought dusty conditions and fluctuating winds, reducing visibility and increasing ...
Insmed is rated a hold, reflecting a robust therapeutic pipeline but persistent unprofitability, and is priced at a high ...
A woman who says the flu vaccine saved her life has urged others to get their jabs as rates rise. Claire Davies was diagnosed ...
Non-cystic fibrosis bronchiectasis (NCFB) is a heterogeneous disease characterised by a ‘vicious vortex’ of ...
Hospitalizations for bronchiectasis exacerbations are associated with poorer in-hospital outcomes than those for chronic obstructive pulmonary disease or asthma exacerbations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback